Zevra reports Q4 net revenue $34.1M, net income $12.2M; appoints Justin Renz as CFO

ZEVRA THERAPEUTICS, INC.

Q4 2025 net revenue $34.1M (+31% QoQ); net income $12.2M ($0.19 diluted EPS) vs. $(35.7)M loss in Q4 2024.
FY 2025 net revenue $106.5M (MIPLYFFA $87.4M); net income $83.2M ($1.35 diluted EPS) vs. $(105.5)M loss in FY 2024.
MIPLYFFA: 24 new prescription enrollment forms in Q4; 52 in 2025; 161 since launch; EU MAA under EMA review, 120-day questions received.
Justin Renz appointed CFO effective March 9, 2026; base salary $520k, 45% target bonus, option grant of 300k shares vesting over 4 years.
Cash, cash equivalents and securities $238.9M at year-end; 56.9M common shares outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.